ID: ALA459142

Max Phase: Preclinical

Molecular Formula: C25H31N7O3

Molecular Weight: 477.57

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCc1ccc(Cn2c(=O)nc(NCCNC3=NCCN3)n(Cc3ccc(OC)cc3)c2=O)cc1

Standard InChI:  InChI=1S/C25H31N7O3/c1-3-18-4-6-19(7-5-18)17-32-24(33)30-23(29-15-14-28-22-26-12-13-27-22)31(25(32)34)16-20-8-10-21(35-2)11-9-20/h4-11H,3,12-17H2,1-2H3,(H2,26,27,28)(H,29,30,33)

Standard InChI Key:  IQQIHJNOLKQKPV-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 477.57

Molecular Weight (Monoisotopic): 477.2488

AlogP: 1.03

#Rotatable Bonds: 10

Polar Surface Area: 114.57

Molecular Species: BASE

HBA: 10

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 10

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 10.88

CX LogP: 2.76

CX LogD: 0.38

Aromatic Rings: 3

Heavy Atoms: 35

QED Weighted: 0.37

Np Likeness Score: -0.83

References

1. Balboni G, Lazzari I, Trapella C, Negri L, Lattanzi R, Giannini E, Nicotra A, Melchiorri P, Visentin S, Nuccio CD, Salvadori S..  (2008)  Triazine compounds as antagonists at Bv8-prokineticin receptors.,  51  (23): [PMID:19006379] [10.1021/jm800854e]

Source

Source(1):

• Scientific Literature